Lovastatin inhibits leukemia cell survival and proliferation in part through suppression of the FAM83A/DDIT4/ERK1/2 pathway, mediated by the induction of the tumor suppressor gene KLF2, as well as cholesterol biosynthesis genes (Fig. 7b). This evidence concerns the gene KLF2 and leukemia.